Press Release:Lords praise Reactive Oxygen® as Innovative Wound Treatment in Parliament Matoke Holdings’ Reactive Oxygen® technology was hailed in the House of Lords yesterday as an innovative product with the potential to transform wound care in the NHS. In a debate on improving NHS standards in wound treatment, Lord Colwyn outlined the efficacy of Reactive Oxygen® in treating hospital spread … Read More
Press Release: MATOKE CALLS FOR FAST TRACK PROCESS TO COMBAT ANTIMICROBIAL RESISTANCE THREAT Matoke Holdings has called on Government to provide a fast-track process to get new drugs to market to combat the global threat of antimicrobial resistance (AMR), at a meeting of key parliamentarians. Representing small and medium-sized companies, Ian Staples, Chief Executive of British biotech Matoke Holdings, called on … Read More
Read our latest newsletter here.
Press Release: Matoke Holdings Ltd™ urges government to prioritise AMR in the Industrial Strategy Matoke Holdings™, a British biotechnology company that has developed a new generation of antimicrobials based on its Reactive Oxygen® technology platform, has urged the Government to prioritise the fight against antimicrobial resistance (AMR) in its flagship Industrial Strategy. In a written submission to the consultation on the … Read More
Press Release: Reactive Oxygen® officially recognised by the NHS through Public Health England (PHE) guidance for common infections Matoke Holdings, the British biotech company developing a new generation of antimicrobials, is delighted to announce its patent-protected Reactive Oxygen® technology is officially recognised in the latest Public Health England (PHE) guidance, ‘Management and Treatment of Common Infections Antibiotic Guidance For Primary Care’. … Read More